Option chain shows key data for Rhinebeck Bancorp's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Rhinebeck Bancorp.

Rhinebeck Bancorp (NASDAQ:RBKB) Stock, Option Chain

Rhinebeck Bancorp

Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank which provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management (RAM). The Bank's primary business activity is accepting deposits from the general public and using those funds to originate indirect automobile loans (automobile loans referred by automobile dealerships), commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and one- to four-family residential real estate loans, and to purchase investment securities.

News

Intraday Update

Markets

Movers

Trading Ideas

ABMD

ACBI

ACCO

ACEL

ACGL

ADOM

AERI

AGEN

AIRG

ALEX

ALLE

ALSN

AMCX

ANTM

AOSL

APYX

AQUA

ARCW

ARES

ARNC

ASRV

ASTC

ATEC

ATHM

ATRS

ATTO

AUTO

AVAL

AVNS

AWSM

AZPN

BANR

BBDO

BCOR

BCSF

BDSI

BECN

BFST

BHLB

BKNG

BMRC

BNED

BOKF

Stocks That Hit 52-Week Lows On Monday

ABCB

ABEV

ACAM

ACER

ACIW

ACLS

ACRS

ACST

AEHR

AGRO

AIMC

AINV

AIRT

ALGN

ALGT

ALOT

AMAL

AMKR

AMOT

AMPH

AMRB

AMSC

AMWD

ANIK

ANIX

APEN

APLE

APOG

APPN

ARCC

ARCO

ARDC

ARDS

ARKR

AROW

ARPO

ATKR

AVNW

AXNX

AZUL

Stocks That Hit 52-Week Lows On Thursday

ACHC

ACRE

ADIL

ADNT

ADTN

ADUS

AFIN

AGCO

AGNC

AGYS

ALKS

ALLY

ALTM

ALYA

AMBC

AMPY

ANAT

APLS

APTV

APTX

APWC

ARGO

AROC

ASGN

ATAX

ATEN

ATNX

ATRA

Stocks That Hit 52-Week Lows On Wednesday

Rhinebeck Bancorp Inc

Life insurance can be a sensitive topic, especially involving elderly parents. On a <a href="https://omny.fm/shows/suze-ormans-women-and-money/ask-kt-suze-anything-should-we-stay-in-the-stock-m">recent episode</a> of her Women and Money podcast, <a href="https://www.benzinga.com/personal-finance/24/12/42537005/35-year-old-says-his-300000-portfolio-was-flagged-as-too-aggressive-for-his-age-asks-suze-orman-if-its-really-time-to-switch-to-bonds">Suze Orman</a> responded to a listener's question about how to help her mother make smarter financial decisions regarding funeral expenses.
The listener, Katina, wrote that her 71-year-old mother has repeatedly applied for whole-life or modified whole-life insurance. Katina's concern is that her mother has health conditions that will prevent her from living long enough for the insurance plans to pay out. With limited funds, Katina asks Orman what she should do to prepare for her mother's funeral expenses.&nbsp;
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
Orman acknowledged the mother's reasoning for seeking life insurance, explaining that these policies are often purchased to cover <a href="https://www.benzinga.com/personal-finance/24/12/42330187/had-to-uber-to-the-funeral-home-and-beg-for-a-ride-this-family-says-dave-ramseys-no-credit-advice-failed-them">funeral costs</a> in the event of an untimely death. "The reason she&#8217;s getting this insurance is that if she dies sooner than later, she has some money to pay for her burial," Orman said.
However, she questioned whether these policies – often marketed on TV for as little as $9.99 per month – are the best use of the mother's limited funds. Instead, Orman encouraged Katina to address the underlying fear driving her mother's decision. "What you need to do is sit down with her and find out how much money she has," Orman suggested, emphasizing the importance of understanding her mother's financial situation and burial preferences.
"Just do a prepaid funeral plan, so she knows that is covered and doesn&#8217;t have to buy insurance anymore," Orman said.&nbsp;
See Also: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
If Katina's mother has enough savings to cover funeral expenses, her mother can pay for funeral services in advance. This option allows her to pay now, often at today's prices, ensuring those costs are covered without relying on insurance.
According to the National Funeral Directors Association (NFDA), the median cost of a burial is $8,300, while the median cost of cremation is $6,280. While Americans struggle with an <a href="https://www.benzinga.com/personal-finance/24/10/41125098/suze-orman-says-the-personal-finance-of-americans-is-really-really-bad-even-though-the-stock-mar">unexpected $400 expense</a>, these costs can shock many people.&nbsp;
If there isn't enough money for a prepaid funeral plan, Orman advised exploring whether Katina or other family members could contribute to prepaying the funeral costs. For families with limited resources, even a small contribution from multiple relatives could help alleviate financial stress.
Trending: <a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a>
However, if neither option is viable, Orman acknowledged that the small life insurance policies Katina's mother is considering might still serve a purpose. "These little policies of $30 a month – that might pay for her funeral expenses, especially if she is not healthy. Might be the way to go, believe it or not," she explained.
Orman's advice centers on addressing the fear behind financial decisions and finding practical solutions tailored to an individual's situation. In this case, Orman says that Katina's best course of action is to have an open and honest conversation with her mother about her financial resources and burial wishes. By exploring prepaid funeral plans or other alternatives, Katina can help her mother find peace of mind without <a href="https://www.benzinga.com/personal-finance/24/09/40837523/suze-orman-isnt-wasting-money-on-insurance-for-her-condo-im-not-paying-28-000-a-year-when-the-in">wasting money on insurance</a> that may not be the best fit.
For listeners grappling with similar concerns, Orman advises careful planning and clear communication when managing end-of-life expenses.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
</ul>

Personal Finance

Listener Asks Suze Orman How To Stop Her Mother From Wasting Money On Life Insurance – Orman Says 'Do A Prepaid Funeral'

Deckers Outdoor's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) short percent of float has fallen 5.7% since its last report. The company recently reported that it has 3.64 million shares sold short, which is 3.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Deckers Outdoor Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734718516_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Deckers Outdoor has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Deckers Outdoor's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Deckers Outdoor's peer group average for short interest as a percentage of float is 6.52%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

DECK

How Is The Market Feeling About Deckers Outdoor?

West Pharmaceutical Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has fallen 10.21% since its last report. The company recently reported that it has 1.16 million shares sold short, which is 2.11% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.32 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734718511_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 5.07%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into West Pharmaceutical Servs's Recent Short Interest

Morgan Stanley analyst Michael Cyprys maintains Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) with a Equal-Weight and raises the price target from $18 to $19.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Invesco, Raises Price Target to $19

WIIM

Warner Bros. Discovery shares are trading higher following reports suggesting CEO David Zaslav is looking to offload assets.

Morgan Stanley analyst Mike Cyprys maintains BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) with a Overweight and raises the price target from $1245 to $1261.

Morgan Stanley Maintains Overweight on BlackRock, Raises Price Target to $1261

<ul>
<li>The U.S. Department of Commerce has awarded TI up to $1.6 billion in CHIPS Act funding to support three new 300mm semiconductor wafer fabs under construction in Texas and Utah.</li>
<li>TI also expects to receive an estimated $6 billion to $8 billion from the U.S. Department of the Treasury's Investment Tax Credit for qualified U.S. manufacturing investments.</li>
<li>The company will also receive up to $10 million to support workforce development.</li>
</ul>
LEHI, Utah and SHERMAN, Texas, Dec. 20, 2024 /PRNewswire/ -- Texas Instruments (TI) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) and the U.S. Department of Commerce today announced an award agreement of up to $1.6 billion in direct funding through the U.S. CHIPS and Science Act, following the preliminary memorandum of terms announced in August 2024. The funding will help support three of TI's new 300mm wafer fabs currently under construction in Texas and Utah.&nbsp;Support from the CHIPS Act, including the 25% investment tax credit, will help TI provide a geopolitically dependable supply of essential analog and embedded processing semiconductors.

Contracts

The U.S. Department Of Commerce Has Awarded TI Up To $1.6B In CHIPS Act Funding To Support 3 New 300mm Semiconductor Wafer Fabs Under Construction In Texas And Utah. TI Also Expects To Receive An ~$6B-$8B From The U.S. Department Of The Treasury's Investment Tax Credit For Qualified U.S. Manufacturing Investments; Will Also Receive Up To $10M To Support Workforce Development

AMZN

GOOG

GOOGL

SNAP

Potential TikTok Bidder Frank McCourt Says He Is Seeking A New CEO For The Company; TikTok Could Earn Revenue From Ecommerce And Data Licensing, Reduce Reliance On Ads

IQVIA Holding shares are trading higher after Stephens & Co initiated coverage on the stock with an Overweight rating on the stock and announced a $250 price target.

<a href="https://x.com/JakeSherman/status/1870162466702770527" title="https://x.com/JakeSherman/status/1870162466702770527">https://x.com/JakeSherman/status/1870162466702770527</a>

Macro Economic Events

Politics

Economics

General

Punchbowl's Jake Sherman Posts On X "JOHNSON said he has spoken to President-elect TRUMP about his new plan." "SCALISE said this about timing: "We're going to be deciding that amongst the membership. there's a plan that gets us there today, if not, we'll do it tomorrow. "

Morgan Stanley analyst Joseph Moore maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Equal-Weight and lowers the price target from $169 to $158.

Morgan Stanley Maintains Equal-Weight on Advanced Micro Devices, Lowers Price Target to $158

U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 300 points on Friday.
The Dow traded up 1.82% to 43,111.11 while the NASDAQ rose 1.77% to 19,714.27. The S&amp;P 500 also rose, gaining, 1.76% to 5,970.36.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a>
Leading and Lagging Sectors Real estate shares jumped by 2.6% on Friday.
In trading on Friday, consumer staples shares rose by just 0.6%.
Top Headline
The U.S. personal consumption expenditures price index rose 0.1% month-over-month in November down from 0.2% in each of the prior two months and compared to market estimates of 0.2%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares shot up 40% to $4.8500 after the company announced FDA approval for SYMVESS for treating extremity vascular injuries. HC Wainwright &amp; Co. raised its price target on the stock from $12 to $15.</li>
<li>Shares of Personalis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>)got a boost, surging 25% to $6.55 after the company and Moderna recently announced a multi-year extension to continue utilizing the Personalis ImmunoID NeXT platform and technology for V940/mRNA-4157. The company also announced an investment from Merck.</li>
<li>Taoping Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares were also up, gaining 31% to $0.4153 after the company announced it received an additional 180 calendar days for compliance with the Nasdaq minimum bid price requirement.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares dropped 74% to $0.4173 as the company reported the pricing of $20.0 million follow on offering.</li>
<li>Shares of Galectin Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) were down 53% to $0.9499 after the company announced top-line results of its NAVIGATE clinical trial and confirmed belapectin did not achieve statistical significance.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) was down, falling 17% to $86.01. The company announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE program.</li>
</ul>
Commodities In commodity news, oil traded down 0.6% to $68.97 while gold traded up 1.5% at $2,645.80.
Silver traded up 1.6% to $29.890 on Friday, while copper rose 0.4% to $4.0925.
Euro zone
European shares were lower today. The eurozone's STOXX 600 dipped 0.99%, Germany's DAX fell 0.59% and France's CAC 40 declined 0.37%. Spain's IBEX 35 Index fell 0.10%, while London's FTSE 100 fell 0.25%.
Consumer confidence in the Eurozone declined by 0.8 points to a reading of -14.5 in December.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 0.29%, Hong Kong's Hang Seng Index falling 0.16%, China's Shanghai Composite Index declining 0.06% and India's BSE Sensex falling 1.49%.
Economics
<ul>
<li>The University of Michigan consumer sentiment rose to 74 in December, recording the highest level since April, and versus a reading of 71.8 in November.</li>
<li>U.S. personal income increased by 0.3% month-over-month in November compared to a revised 0.7% gain in October.</li>
<li>Personal spending increased by 0.4% to an annualized rate of $20.2 trillion in November.</li>
<li>The U.S. personal consumption expenditures price index rose 0.1% month-over-month in November down from 0.2% in each of the prior two months and compared to market estimates of 0.2%.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42616304/top-3-risk-off-stocks-that-may-collapse-this-month">Top 3 Risk Off Stocks That May Collapse This Month</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

GALT

HUMA

PSNL

TAOP

Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher

White House Says Republicans Need To Stick With Bipartisan Deal To Keep The Government Open

AVGO

Broadcom shares are trading higher. Morgan Stanley maintained its Overweight rating on the stock and raised its price target from $233 to $265

Econ #s

U.S. Baker Hughes Oil Rig Count +1 At 483; U.S. Baker Hughes NatGas Rig Count -1 At 102

Morgan Stanley analyst Joseph Moore maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Equal-Weight and raises the price target from $102 to $120.

MRVL

Morgan Stanley Maintains Equal-Weight on Marvell Tech, Raises Price Target to $120

COLB

CNBC Halftime Report Final Trades: Freeport-McMoRan, Columbia Banking System, The Procter & Gamble Company, Target

SSNLF

U.S. Commerce Department Finalizes Up To $4.745B Chips Subsidy For Samsung Electronics, Significantly Less Than Initially Proposed; U.S. Finalizes Up To $1.6B Subsidy For Texas Instruments For Factories In Texas And Utah

Morgan Stanley analyst Joseph Moore maintains Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Overweight and raises the price target from $94 to $142.

ALAB

Morgan Stanley Maintains Overweight on Astera Labs, Raises Price Target to $142

10 analysts have expressed a variety of opinions on Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Paychex and provided 12-month price targets. The average target is $138.9, accompanied by a high estimate of $148.00 and a low estimate of $130.00. Witnessing a positive shift, the current average has risen by 8.77% from the previous average price target of $127.70.
<img src="https://www.benzinga.com/files/images/story/2024/1734717653_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Paychex among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$148.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$139.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$131.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$141.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$148.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Kevin Mcveigh</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$142.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$133.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Peter Christiansen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$132.00</td>
<td>$118.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Paychex. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Paychex compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Paychex's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Paychex's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PAYX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Paychex analyst ratings.</a>
<h2>Get to Know Paychex Better</h2>
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, founded in 1971, services over 745,000 clients and pays 1 in 12 US private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
<h3>Key Indicators: Paychex's Financial Health</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Paychex showcased positive performance, achieving a revenue growth rate of 2.53% as of 31 August, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Paychex's net margin is impressive, surpassing industry averages. With a net margin of 32.42%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Paychex's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 11.17%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Paychex's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.1%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.23, Paychex adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PAYX

Demystifying Paychex: Insights From 10 Analyst Reviews

Rhinebeck Bancorp GAAP EPS of $0.10, revenue of $10.40M

Rhinebeck Bancorp appoints CFO

The latest update is out from Rhinebeck Bancorp (RBKB). Kevin Nihill has been appointed as Chief Financial Officer and Treasurer of Rhinebeck Banco...

Rhinebeck Bancorp Announces CFO Appointment and Compensation Details

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Rhinebeck Bancorp (NASDAQ:<a href="https://investorplace.com/stock-quotes/rbkb-stock-quote/">RBKB</a>) just reported results for the second quarter of 2024.<ul><li>Rhinebeck Bancorp reported earnings per share of 9 cents.</li><li>The company reported revenue of $10.65 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/07/rbkb-stock-earnings-rhinebeck-bancorp-for-q2-of-2024/">RBKB Stock Earnings: Rhinebeck Bancorp Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RBKB Stock Earnings: Rhinebeck Bancorp Reported Results for Q2 2024

Rhinebeck Bancorp GAAP EPS of $0.09, revenue of $10.65M

Rhinebeck Bancorp ( ($RBKB) ) just unveiled an announcement. Rhinebeck Bank's Board of Directors has decided not to renew the employment contracts ...

Rhinebeck Bancorp Announces Executive Contract Strategy Shift

Get Your Winners To Pay For Your Losers With Chris DeMuth And Kirk Spano

Fed's Pivot To Lower Rates Could Spur More Bond Restructuring

Banks, Thrifts, And Takeover Candidates

Rhinebeck Bancorp Non-GAAP EPS of $0.13

Comments

Rhinebeck Bancorp

Rhinebeck Bancorp (RBKB) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga